methyl 3-(2-tert-butoxy-2-oxoethoxy)-5-hydroxybenzoate | 206053-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(2-tert-butoxy-2-oxoethoxy)-5-hydroxybenzoate
• 英文别名: Methyl 3-hydroxy-5-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]benzoate
• CAS: 206053-75-0
• 化学式: C₁₄H₁₈O₆
• 分子量: 282.293
• InChiKey: NILWFQXFINRYSU-UHFFFAOYSA-N

物化性质

• 沸点：
  411.5±30.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 3-(2-tert-butoxy-2-oxoethoxy)-5-hydroxybenzoate 在 sodium hydroxide 、 potassium carbonate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 3-[3-(tri-O-benzyl-α-L-fucopyranosyl)-1-propyloxy]-5-methoxycarbonylphenoxyacetic acid
  参考文献：
  名称：

  Synthesis of novel Sialyl-LewisX glycomimetics as selectin antagonists

  摘要：

  A series of low molecular weight sialyl-Lewis(X) analogs based on either rigid or flexible replacements for the carbohydrates were designed as orally available anti-inflammatory drugs, synthesized and tested in cell-based adhesion assays. The flexible glycomimetic 7a lacking any glycoside or peptide linkage was prepared in 4 steps and 41% overall yield from methyl 3,5-dihydroxybenzoate and the fucose derivative 18 and exhibited about equal binding affinity to E-and P-selectin compared to the parent tetrasaccharide. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00105-7
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 3,5-二羟基苯甲酸甲酯 在 15-冠醚-5 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以34%的产率得到methyl 3-(2-tert-butoxy-2-oxoethoxy)-5-hydroxybenzoate
  参考文献：
  名称：

  小分子非肽活性位点β分泌酶抑制剂的鉴定，该抑制剂显示天冬氨酰蛋白酶的非传统结合模式。

  摘要：

  已经开发出β-分泌酶的小分子非肽抑制剂，并通过晶体学测定酶-抑制剂复合物来确定其结合。在天冬氨酰蛋白酶抑制领域，该分子以前所未有的方式与催化的天冬氨酸残基结合。另外，该复合物揭示了由抑制剂产生的迄今未知的S（3）亚型。这种结构在设计新型β-分泌酶抑制剂中起着重要作用。

  DOI：

  10.1021/jm049388p

文献信息

• [EN] PHENYL CARBOXAMIDE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] COMPOSÉS DE PHÉNYL CARBOXAMIDE UTILISABLES COMME INHIBITEURS DE BÊTA SÉCRÉTASE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005113484A1

  公开（公告）日：2005-12-01

  The present invention is directed to phenyl carboxamide compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及苯基羧酰胺化合物，这些化合物是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物以及在治疗β-分泌酶酶参与的这类疾病中使用这些化合物和组合物。
• PHENYL CARBOXAMIDE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Merck & Co., Inc.

  公开号：EP1756040A1

  公开（公告）日：2007-02-28
• EP1756040A4
  申请人：——

  公开号：EP1756040A4

  公开（公告）日：2008-04-30
• Phenyl Carboxamide Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Coburn A. Craig

  公开号：US20070254958A1

  公开（公告）日：2007-11-01

  The present invention is directed to phenyl carboxamide compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
• US7449599B2
  申请人：——

  公开号：US7449599B2

  公开（公告）日：2008-11-11